Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases
Abstract Adoptive immunotherapy using engineered T cells expressing chimeric antigen receptors has shown remarkable success in treating patients with hematological malignancies. However, realizing broader therapeutic applications of engineered T cells in other diseases requires further exploration i...
Saved in:
Main Authors: | Qiaolin Huang, Xiaojian Zhu, Yicheng Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-02-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40364-025-00736-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
T-regulatory cells for the treatment of autoimmune diseases
by: Marina S. Fisher, et al.
Published: (2025-02-01) -
Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01) -
The role of BATF in immune cell differentiation and autoimmune diseases
by: Xiaomeng Wang, et al.
Published: (2025-01-01) -
Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer
by: Lijuan Qin, et al.
Published: (2025-02-01) -
Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
by: Alice Sýkorová, et al.
Published: (2024-09-01)